Facebook-f Twitter Linkedin Youtube
SUBSCRIBE
Facebook-f Twitter Linkedin Youtube

Rheumatology CE Activities

RMEI PRESENTATIONS

View Details

Proficiency Results From Your Peers at EULAR 2018 and Beyond – Infographic

Proficiency results from your peers at EULAR 2018 and beyond. Topics discussed at our EULAR 2018 symposium. How Cytokines affect RA | Disease Monitoring | When to switch VS cycle drugs | Shared decision making (SDM).
Presentation Year: 2020
Presented at: European Alliance of Associations for Rheumatology (EULAR)
View Details

Proficiency Results From Your Peers at EULAR 2018 and Beyond

Beginning in 2016, RMEI created multiple accredited online educational programs focused on rheumatoid arthritis (RA) and designed for rheumatologists. The 2019 EULAR symposium was a unique opportunity to present the outcomes findings, from both the 2018 symposium and online courses, to the assembled rheumatologists within the context of addressing factors underlying ongoing educational gaps.
Presentation Year: 2020
Presented at: European Alliance of Associations for Rheumatology (EULAR)
View More Presentations

LATEST RHEUMATOLOGY ARTICLES

RSS Latest Rheumatology Articles
  • Myasthenia Gravis — Redemption for B-Cell Depletion June 19, 2025
    Myasthenia gravis, an immune-mediated neurologic disorder, has for the past century been treated effectively with various immunotherapies, ranging from thymectomy to approved targeted agents.1,2 The neuromuscular transmission defect of myasthenia gravis is driven by autoreactive immunoglobulins directed postsynaptically. Hence, it is no large leap to posit that therapies...
    Gil I. Wolfe, Shahar Shelly
  • Unruptured Intracranial Aneurysms June 19, 2025
    Intracranial aneurysms are common, and the risk of rupture is influenced by size, location, morphology, and factors such as hypertension, smoking, and family history. Management options and risks are discussed.
    Christopher S. Ogilvy
  • A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis June 19, 2025
    In adults with myasthenia gravis, treatment with intravenous inebilizumab, a CD19-specific monoclonal antibody, significantly improved function and reduced disease severity at 26 weeks.
    Richard J. Nowak, Michael Benatar, Emma Ciafaloni, James F. Howard Jr., M. Isabel Leite, Kimiaki Utsugisawa, John Vissing, Mikhail Rojavin, Qing Li, Fengming Tang, Yanping Wu, Nishi Rampal, Sue Cheng, the MINT Investigators*

RMEI LIGHTNING TALKS

View Details

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.
  • Allergy & Immunology
  • 2021
View Details

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.
  • Gastroenterology
  • 2021

Previously Published CE Activities

Copyright © 2025. RMEI Medical Education, LLC. All rights reserved​